RXRα/MR signaling promotes diabetic kidney disease by facilitating renal tubular epithelial cells senescence and

Qijian Feng1, Chang Su2, Chuyi Yang2

  • 1Department of Endocrinology & Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China. 510515; Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, PR China.

Insights

Retinoid X receptor alpha (RXRα) drives cell senescence and metabolic issues in diabetic kidney disease. Inhibiting RXRα/mineralocorticoid receptor (MR) signaling improves kidney function and reduces senescence in DKD models.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Diabetic kidney disease (DKD) is characterized by cell senescence and metabolic reprogramming.
  • The interplay between these processes in DKD remains unclear.

Purpose of the Study:

  • To investigate the role of retinoid X receptor alpha (RXRα) in regulating cell senescence and metabolic reprogramming in DKD.
  • To elucidate the underlying molecular mechanisms, including interactions with the mineralocorticoid receptor (MR).

Main Methods:

  • High-throughput sequencing, bioinformatic analysis, and experimental validation in renal tubular epithelial cells (RTECs).
  • In vivo studies using AAV9-shRxra in DKD mice.
  • In vitro knockdown of RXRα.
  • Protein-protein interaction (PPI) analysis, coimmunoprecipitation, and gene network analysis.
  • Studies in an accelerated aging mouse model using a MR antagonist.

Main Results:

  • RXRα promotes cell senescence and metabolic dysregulation in lipid-overloaded RTECs.
  • Kidney-specific RXRα knockdown in DKD mice reduced proteinuria, RTEC senescence, and insulin resistance.
  • RXRα directly interacts with MR, collaboratively regulating RTEC senescence.
  • MR antagonist treatment in aging mice inhibited RXRα/MR signaling, improving kidney senescence and fibrosis.

Conclusions:

  • RXRα is a critical regulator of cell senescence and metabolic reprogramming in DKD.
  • The RXRα/MR signaling pathway mediates the crosstalk between senescence and metabolic disorders in the kidney.
  • Targeting RXRα/MR signaling offers a potential therapeutic strategy for DKD and related metabolic conditions.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K